1,4-Dihydroindeno[1,2-c]pyrazoles as potent checkpoint kinase 1 inhibitors: Extended exploration on phenyl ring substitutions and preliminary ADME/PK studies

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 13, 2007, Pages 3618-3623

  Tong, Yunsong ^a   Claiborne, Akiyo ^a   Pyzytulinska, Magdalena ^a   Tao, Zhi Fu ^a   Stewart, Kent D ^a   Kovar, Peter ^a   Chen, Zehan ^a   Credo, Robert B ^a   Guan, Ran ^a   Merta, Philip J ^a   Zhang, Haiying ^a   Bouska, Jennifer ^a   Everitt, Elizabeth A ^a   Murry, Bernard P ^a   Hickman, Dean ^a   Stratton, Tim J ^a   Wu, Jian ^a   Rosenberg, Saul H ^a   Sham, Hing L ^a   Sowin, Thomas J ^a   Lin, Nan horng ^a   more..

^a ABBOTT LABORATORIES   (United States)

Author keywords

1,4 Dihydroindeno 1,2 c pyrazoles; Checkpoint kinase 1 inhibitors; Chk 1 inhibitors; Sensitizing DNA damaging agents

Indexed keywords

CHECKPOINT KINASE 1; DOXORUBICIN; PYRAZOLE DERIVATIVE;

ARTICLE; DRUG ACTIVITY; HELA CELL; HUMAN; HUMAN CELL; IC 50; METABOLIC PARAMETERS; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY;

ANIMALS; ANTINEOPLASTIC AGENTS; CACO-2 CELLS; CHEMISTRY, PHARMACEUTICAL; DNA DAMAGE; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; FLOW CYTOMETRY; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MICROSOMES, LIVER; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; RATS;

EID: 34250196523     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.04.055     Document Type: Article

References (18)

1. For reviews, see. Zhou B.B., and Bartek J. Nat. Rev. Cancer 4 (2004) 1
2. Tao Z.-F., and Lin N.-H. Anti-Cancer Agents Med. Chem. 6 (2006) 377
3. Xiao Z., Chen Z., Gunasekera A.H., Sowin T.J., Rosenberg S.H., Fesik S., and Zhang H. J. Biol. Chem. 278 (2003) 21767
4. Mailand N., Falck J., Lukas C., Syljuåsen R.G., Welcker M., Bartek J., and Lukas J. Science 288 (2000) 1425
5. Zhao H., Watkins J.L., and Piwnica-Worms H. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 14795
6. Powell S.N., DeFrank J.S., Connell P., Eogan M., Preffer F., Dombkowski D., Tang W., and Friend S. Cancer Res. 55 (1995) 1643
7. Kuerbitz S.J., Plunkett B.S., Walsh W.V., and Kastan M.B. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 7491
8. Tong Y., Claiborne A., Stewart K.D., Park P., Kovar P., Chen Z., Credo R.B., Gu W.-Z., Gwaltney II S.L., Judge R.A., Zhang H., Rosenberg S.H., Sham H.L., Sowin T.J., and Lin N.H. Bioorg. Med. Chem. 15 (2007) 2759
9. Doyle, K.; Rafferty, P.; Steele, R.; Turner, A.; Wilkins, D.; Arnold, L. Therapeutic agents. US 6297238.
10. Yin J., and Buchwald S.L. Org. Lett. 2 (2000) 1101
11. Anastasis P., and Brown P.E. J. Chem. Soc. Perkin Trans. 1 (1982) 2013
12. Compounds 8 and 9 were synthesized from known starting materials, 5-hydroxy-2,3-dihydro-1H-inden-1-one and 3-iodo-1,4-dihydroindeno[1,2-c]pyrazole-6-carbaldehyde, respectively, following similar procedures shown in this article.
13. 33P were used. The concentration of the vehicle, DMSO, in the final reaction is 2%. After 30 min at room temperature, the reaction was stopped by the addition of equal volume of 4 M NaCl and 0.1 M EDTA (pH 8.0). A 40 μL aliquot of the reaction mixture was added to a well in a Flash Plate (NEN Life Science Products, Boston, MA) containing 160 μL of phosphate-buffered saline (PBS) without calcium chloride and magnesium chloride and incubated at room temperature for 10 min. The plate was then washed three times in PBS with 0.05% of Tween 20 and counted in a Packard TopCount counter (Packard BioScience Company, Meriden, CT).
14. See Ref. 4 for detailed X-ray co-crystal structures with coordinated deposited in the PDB.
15. See Ref. 4 for assay conditions and representative raw data.
16. Fraley M.E., Steen J.T., Brnardic E.J., Arrington K.L., Spencer K.L., Hanney B.A., Kim Y., Hartman G.D., Stirdivant S.M., Drakas B.A., Rickert K., Walsh E.S., Hamilton K., Buser C.A., Hardwick J., Tao W., Beck S.C., Mao X., Lobell R.B., Sepp-Lorenzino L., Yan Y., Ikuta M., Munshi S.K., Kuo L.C., and Kreatsoulas C. Bioorg. Med. Chem. Lett. 16 (2006) 6049
17. Yee S. Pharm. Res. 14 (1997) 763
18. Madsen P., Ling A., Plewe M., Sams C.K., Knudsen L.B., Sidelmann U.G., Ynddal L., Brand C.L., Anderson B., Murphy D., Teng M., Truesdale L., Kiel D., May J., Kuki A., Shi S., Johnson M.D., Teston K.A., Feng J., Lakis J., Anderes K., Gregor V., and Lau J. J. Med. Chem. 45 (2002) 5755